

OPTIMA HEALTH FAMILY CARE (MEDICAID)

PHARMACY/MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-723-2094.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **Incomplete form will delay authorization process.**

Drug Requested: **Radicava™ (edaravone) IV (Codes C9399/J3490) (Medical)**

DRUG INFORMATION: Complete information below or authorization process will be delayed.

Drug Form/Strength: _____

Dosing Schedule: _____ **Length of Therapy:** _____

Diagnosis: _____ **ICD Code, if applicable:** _____

CLINICAL CRITERIA: **ALL** information below **MUST** be checked to qualify or authorization process will be delayed. Submission of medical records (e.g., chart notes, previous medical history, diagnostic testing to include imaging, nerve conduction studies, lab values) **MUST** be submitted with this request.

Initial Approval – Length is for 6 months
(no more than 86 doses over 180 days)

- Prescriber is an Neurologist**
 - Patient is \geq 18 years of age
 - Patient has diagnosis of “definite” or “probable” amyotrophic lateral sclerosis (ALS) per the EL Escorial

AND

- Functionality retained most activities of daily living (defined as scores of 2 points or better on each individual item of the ALS Functional Rating Scale-Revised (ALSFRS-R) **(please submit)**)

AND

- Normal respiratory function confirming patient has a % forced vital capacity (%FVC) \geq 80% at the start of treatment **(medical records must be attached)**

AND

- Disease duration of two (2) years or less **(progress notes must document date)**

Radicava™ is considered an Exclusion for score of 3 or less on ALSFRS-R items for dyspnea, orthopnea, or respiratory insufficiency; history of spinal surgery after onset of ALS.

Reauthorization Approval – Length is for 6 months
(no more than 86 doses over 180 days)

- Functionality retained most activities of daily living (defined as score from baseline did not decrease on each individual item of the ALS Functional Rating Scale-Revised (ALSFRS-R))

(continued on next page)

